8 results
Primary: Longterm safety and tolerability.Secondary: Time to 1st flare, number and severity of flares, efficiacy in treating flares, effect on inflammatory markers, immunogenicity, PK.
Primary: To confirm that canakinumab 150 mg s.c. is superior to triamcinolone acetonide 40 mg i.m. with respect to patient*s assessment of gout pain intensity in the target joint at 72 hours post-dose (on a 0-100mm VAS). To confirm that canakinumab…
This study aims to investigate the effect of switching from Atripla® to Eviplera® on neurocognitive performances (neurocognitive testing) and imaging (functional MRI scanning) in virologically suppressed HIV-infected patients and stable on atripla.
The primary objective of this study is to evaluate whether adding intensive local anti-inflammatory therapy (Triamcinolone injection therapy combined with 9 mg oral BudenoFalk once daily for 24 weeks) to routine enteric balloon dilatation reduces…
Primary objective:To evaluate the efficacy of a RPV based HAART in patients that switch from NVP with FTC, TDF or lamivudine (3TC), TDF or 3TC, zidovudine (ZDV) to RPV/FTC/TDF.Secondary objectives:To measure the impact (strength and duration) of NVP…
This study aims to investigate the effect of switching from Atripla® to Eviplera® on neurocognitive performances (neurocognitive testing) and imaging (functional MRI scanning) in virologically suppressed HIV-infected patients and stable on atripla.
4.1 Primary Objective• To determine the MTD and to establish the safety profile of enapotamab vedotin in a mixed population of patients with specified solid tumors. 4.2 Secondary Objectives• To evaluate the safety laboratory parameters of enapotamab…
The primary objective is to find out whether ISI in children with EA can prevent refractory strictures from developing and consequently can reduce the total number of dilatations needed within 28 days interval.